Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.44 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14822843 | 1.00 | EPHX1 (0.56) | EPHX1ALDH1A1HPGDCYP19A1TRPA1 | |
| SCHEMBL13253745 | 1.00 | EPHX1 (0.56) | EPHX1ALDH1A1HPGDCYP19A1TRPA1 | |
| SCHEMBL20719903 | 1.00 | EPHX1 (0.56) | EPHX1ALDH1A1HPGDCYP19A1TRPA1 | |
| SCHEMBL20328573 | 1.00 | EPHX1 (0.56) | EPHX1ALDH1A1HPGDCYP19A1TRPA1 | |
| SCHEMBL19670085 | 1.00 | EPHX1 (0.56) | EPHX1ALDH1A1HPGDCYP19A1TRPA1 | |
| SCHEMBL10139342 | 1.00 | EPHX1 (0.56) | EPHX1ALDH1A1HPGDCYP19A1TRPA1 | |
| SCHEMBL21623926 | 0.89 | EPHX1 (0.55) | EPHX1ALDH1A1HPGDCYP19A1TRPA1 | |
| SCHEMBL130771 | 0.85 | EPHX1 (0.51) | EPHX1ALDH1A1HPGDCYP19A1TRPM8 | |
| SCHEMBL27975519 | 0.85 | EPHX1 (0.54) | EPHX1ALDH1A1HPGDCYP19A1TRPA1 | |
| SCHEMBL5358744 | 0.84 | EPHX1 (0.50) | EPHX1ALDH1A1HPGDCYP19A1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834568-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9725419-B2 | Cycloalkyl substituted pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725419-B2 | Cycloalkyl substituted pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160024116-A1 | Kinase Inhibitors And Their Uses | MIDCAP FINANCIAL TRUST | 2016-01-28 | — | — | US | disclosed |
| US-9096542-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20130210814-A1 | Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-8410093-B2 | Cycloalkyl substituted pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20120015937-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-8053434-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-20110152518-A1 | Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| US-7868013-B2 | Cycloalkyl substituted pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-7858633-B2 | Cycloalkyl substituted pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7754714-B2 | (1S, 2R)-N4-(2-Aminocarbonylcyclopent-1-yl)-5-fluoro-N2-[4-(4-methylpiperazin-1-yl)-3-methylphenyl]-2,4-pyrimidinediamine, having antiproliferative activity, used to inhibit cellular proliferation and to treat proliferate diseases such as cancers | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20100069369-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-7601713-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20080009494-A1 | Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-20070299060-A1 | Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070142402-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152518-A1 | Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses | MKI67, PCNA, TK1 | EPHX1 2764/4885ALDH1A1 1807/4885HPGD 1278/4885 |
| US-20070299060-A1 | Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses | MKI67, PCNA, TK1 | EPHX1 2764/4885ALDH1A1 1807/4885HPGD 1278/4885 |
| US-20120015937-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, LYN | EPHX1 3454/4885ALDH1A1 4690/4885HPGD 4354/4885 |
| US-20080009494-A1 | Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses | MKI67, PCNA, TK1 | EPHX1 2764/4885ALDH1A1 1807/4885HPGD 1278/4885 |
| US-20160024116-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, LYN | EPHX1 3454/4885ALDH1A1 4690/4885HPGD 4354/4885 |
| US-20130210814-A1 | Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses | MKI67, PCNA, TK1 | EPHX1 2764/4885ALDH1A1 1807/4885HPGD 1278/4885 |
| US-20100069369-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, JAK2 | EPHX1 2891/4885ALDH1A1 4480/4885HPGD 3492/4885 |
| US-20070142402-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, LYN | EPHX1 3454/4885ALDH1A1 4690/4885HPGD 4354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.